IGF-1, IGFBP3, ALS Normative Ranges in Healthy Pediatric Spanish Population
NCT01676090 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 304
Last updated 2019-01-11
Summary
To determine the normative ranges of the Insulin-like Growth Factor 1 (IGF-1), Insulin-like growth factor-binding protein 3 (IGFBP-3), Acid-Labile Subunit (ALS) according to age, sex and pubertal stage of a healthy paediatric Spanish population.
Conditions
- IGF-1 Deficiency
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Ipsen Medical Director · Ipsen
Eligibility
- Max Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2012-07-31
- Primary Completion
- 2013-10-31
- Completion
- 2013-10-31
Countries
- Spain
Study Locations
More Related Trials
-
Treatment of Children and Adolescents With Growth Failure Associated With Primary IGF-1 Deficiency
NCT00330668 ·Status: TERMINATED ·Phase: PHASE3
-
Retrospective Study Of The Influence Of Age At Start Of Growth Hormone Treatment On Height Gain In Children Born Small for Gestational Age
NCT01897753 ·Status: COMPLETED
-
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
NCT00903110 ·Status: RECRUITING
-
Predictive Value of the Insulin-like Growth Factor-1 (IGF-1) Generation Test for the Growth Response to Growth Hormone Treatment (PRED-IGF)
NCT01438801 ·Status: WITHDRAWN ·Phase: PHASE4
-
The IGFBP-3 Stimulation Test: A New Tool for the Diagnosis of Growth Hormone Deficiency in Children.
NCT00235599 ·Status: COMPLETED
-
Evaluation of Infants With Intrauterine Growth Restriction
NCT02515292 ·Status: UNKNOWN
-
Safety Profile of Insulin Like Growth Factor-1 (IGF-I) Administration in Adolescents
NCT00516386 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study Aimed At Improving Height With Genotonorm In Children Born Little And/Or Light With Growth Retardation At The Age
NCT00174252 ·Status: COMPLETED ·Phase: PHASE3
-
Constructing an Insulin-Like Growth Factor-based Prediction Model
NCT00263445 ·Status: TERMINATED
-
Measurement of Outcome of Surgical Treatment in Patients With Acromegaly
NCT00005100 ·Status: UNKNOWN
-
A Prospective Sub-Study of the Global Hypophosphatasia Registry
NCT05234567 ·Status: RECRUITING
-
Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) Deficiency
NCT00125164 ·Status: COMPLETED ·Phase: PHASE3
-
The Role of Igf-1 Generation Test in Diagnosis and Treatment of Short Stature
NCT01970800 ·Status: WITHDRAWN ·Phase: NA
-
Evolution Of Growth Rate In Children With Growth Retardation Due to Glucocorticosteroid Therapy And Treated By Genotonorm
NCT00163189 ·Status: COMPLETED ·Phase: PHASE3
-
Growth Hormone (GH) Deficiency & Insulin Like Growth Factor 1 (IGF-I)/ Insulin Like Growth Factor Binding Protein 3 (IGFBP-3) Ratio
NCT02424240 ·Status: COMPLETED
-
Non-interventional Study of Patients Using Norditropin® for Growth Hormone Deficiency or Turner Syndrome
NCT01604161 ·Status: COMPLETED
-
A Long-Term Safety Trial of LUM-201 in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed a LUM-201 Clinical Trial (OraGrowtH211)
NCT05796440 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2
-
Inter-Assay Growth Hormone and IGF-I Variability
NCT00638287 ·Status: WITHDRAWN
-
Impact of GH Measurements on GHD Diagnosis
NCT04508673 ·Status: COMPLETED
-
Is There a Sensibility Increased in the Growth Hormone at Child With Prader-Willi Syndrome?
NCT01298180 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of the Genetic Basis of Response to Growth Hormone Treatment in Children With Idiopathic Short Stature
NCT05894876 ·Status: TERMINATED
-
Eisenmenger Syndrome in the Nordic Countries
NCT01976533 ·Status: UNKNOWN
-
A Post Marketing Surveillance Program for NutropinAq® in Paediatric Growth Disorders
NCT00455728 ·Status: COMPLETED
-
Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) in Acromegalic Subjects
NCT02807233 ·Status: COMPLETED
-
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome
NCT02713945 ·Status: COMPLETED ·Phase: PHASE3